Want to see FR:ABNX full AI Analyst Report?
Top Page
ABIONYX Pharma SA
(ABNX)
Select Model
Select Model
Rating:42Neutral
Price Target:
€2.00
▼(-45.95% Downside)
Action:Reiterated
Date:07/08/26
The score is held down primarily by weak financial performance (persistent large losses, ongoing cash burn, and reduced balance-sheet flexibility from lower equity and higher leverage). Technicals also remain unfavorable with a clear downtrend, though the stock is oversold. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Platform focus on apoA‑I R&D
A focused scientific platform around apoA‑I and HDL biology provides a durable strategic advantage: it can generate multiple clinical candidates across inflammatory and infectious indications, leverage translational research expertise, and concentrate R&D resources on biologically supported targets over the next several months to years.
Negative Factors
Persistent negative cash generation
Consistent and material cash outflows (~-€2.93m operating, ~-€3.18m free cash flow in 2025) create ongoing financing needs. Over months this structural cash burn forces reliance on capital markets or debt, raising dilution or leverage and constraining strategic flexibility absent a clear step‑change in revenues or milestone receipts.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform focus on apoA‑I R&D
A focused scientific platform around apoA‑I and HDL biology provides a durable strategic advantage: it can generate multiple clinical candidates across inflammatory and infectious indications, leverage translational research expertise, and concentrate R&D resources on biologically supported targets over the next several months to years.
Read all positive factors
ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€78.50M
Dividend YieldN/A
Average Volume (3M)284.77K
Price to Earnings (P/E)―
Beta (1Y)-0.42
Revenue Growth-10.72%
EPS Growth-21.24%
CountryFR
Employees51
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding42,568,070
10 Day Avg. Volume172,880
30 Day Avg. Volume284,772
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
ABIONYX Pharma SA Business Overview & Revenue Model
Company Description
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. T...
How the Company Makes Money
null...
ABIONYX Pharma SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.06M | 4.60M | 4.64M | 5.25M | 675.00K |
| Gross Profit | 376.00K | 844.00K | 618.00K | 636.00K | 259.00K |
| EBITDA | -5.70M | -4.93M | -4.53M | -4.01M | -7.42M |
| Net Income | -5.55M | -4.40M | -3.52M | -4.21M | -5.82M |
Balance Sheet | |||||
| Total Assets | 12.86M | 13.45M | 14.83M | 15.82M | 21.83M |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 3.23M | 4.10M | 4.05M | 7.93M |
| Total Debt | 3.81M | 3.10M | 3.39M | 4.01M | 4.96M |
| Total Liabilities | 8.60M | 6.03M | 6.91M | 8.65M | 11.15M |
| Stockholders Equity | 4.26M | 7.42M | 7.92M | 7.17M | 10.68M |
Cash Flow | |||||
| Free Cash Flow | -3.17M | -3.60M | -3.83M | -3.53M | -6.86M |
| Operating Cash Flow | -2.93M | -3.60M | -3.70M | -3.36M | -6.69M |
| Investing Cash Flow | -205.00K | -100.00K | -130.00K | -175.00K | 1.34M |
| Financing Cash Flow | 3.42M | 2.80M | 3.89M | -194.00K | 3.97M |
ABIONYX Pharma SA Technical Analysis
Negative
3.70
Price Trends
2.82
Negative
3.11
Negative
3.42
Negative
Market Momentum
-0.25
Negative
18.27
Positive
6.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Negative. The current price of 3.7 is above the 20-day moving average (MA) of 2.22, above the 50-day MA of 2.82, and above the 200-day MA of 3.42, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 18.27 is Positive, neither overbought nor oversold. The STOCH value of 6.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABNX.
ABIONYX Pharma SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:ABNX
ABIONYX Pharma SA
1.94
0.75
62.89%
FR:ALCOX
Nicox SA
0.39
0.16
71.56%
FR:SIGHT
GenSight Biologics SA
0.08
-0.05
-35.94%
FR:ALSEN
Sensorion SAS
0.26
-0.07
-20.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.